Quell Therapeutics

Uncover our world leading platform

Uncover our world leading platform

On the pursuit to develop the most stable and potent targeted Treg cell therapies

Quell Slider 2

Tregs

The masters of immune tolerance

Regulatory T cells (Tregs) are the body's masterful immune modulators, expertly orchestrating the immune system to strike the perfect balance between immune defence and self tolerance

Our Platform

with the optimal cell product at our core and a suite of innovative technologies to ensure continued trailblazing progress

Quell Slider 2

Core Platform

Stability
Phenotype-Lock™ Tregs

Quell leverages its cutting-edge Phenotype Lock technology to revolutionize the Treg cell therapy approach. By transducing the cells with the Treg master transcription factor, FOXP3, we ensure sustained and robust FOXP3 expression at all times. This innovative approach locks Tregs in a highly stable and suppressive state, empowering them to effectively modulate immune responses and withstand inflammatory challenge. Our ground-breaking technology amplifies the therapeutic potential of Tregs, setting a new standard in immune regulation and tolerance induction.

Manufacturing Process

We are a clinical stage company at the forefront of the Treg cell therapy field. With deep GMP experience and over several hundred scale runs to date, we pride ourselves on the continued delivery of the highest manufacturing standards. Our experience at therapeutic scale has driven significant improvements, making our manufacturing process highly efficient, stable, and effective for delivering transformative cell products to patients.